

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2020-21

Date: 13.08.2020

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2020.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2020 as **Annexure-A** and
- Limited Review Report on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- An Investor Release on the financial results is enclosed at **Annexure-C**.

Further Board of Directors at their meeting approved the following resolutions:

- Approved draft Annual Report for the financial year 2019-20.
- Approved the re-appointment of Mr. Harish Pande (DIN: 01575625) as Non- Executive Independent Director of the Company subject to the approval of shareholders at the ensuing Annual General Meeting.
- Approved the re-appointment of Mr. Suresh Kumar Singh (DIN: 00318015) as Non- Executive, Director of the Company subject to the approval of shareholders at the ensuing Annual General Meeting.

The meeting of the Board of Directors commenced 2.00 p.m. and concluded at 3.40 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2020, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited



Rahul Bishnoi
Chairman

MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the quarter ended on 30th June 2020

PART I

Particulars	Standalone				Consolidated			
	Quarter Ended			Year Ended	Quarter Ended			Year Ended
	3 Months Ended 30.06.2020	Preceding 3 Months Ended 31.03.2020	Corresponding 3 Months Ended 30.06.2019	31.03.2020	3 Months Ended 30.06.2020	Preceding 3 Months Ended 31.03.2020	Corresponding 3 Months Ended 30.06.2019	31.03.2020
	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited
1 Income from operations								
(a) Net Sales / Income from operations	2,611.52	1,536.33	3,112.91	11,734.23	2,778.35	2,352.47	3,112.91	12,550.38
(b) Other Income	8.41	106.64	3.84	190.86	8.41	109.67	3.84	193.88
(c) Total Revenue	2,619.93	1,642.97	3,116.75	11,925.09	2,786.76	2,462.14	3,116.75	12,744.26
2 Expenses								
a) Cost of Material Consumed	1,657.04	944.11	2,154.07	7,449.16	1,798.17	1,540.25	2,154.07	8,045.29
b) Purchase of Goods Traded	-	-	-	-	-	-	-	-
c) Changes in inventory of Finished Goods and Work in Progress	38.10	(232.99)	(69.75)	(153.25)	38.10	(232.99)	(69.75)	(153.25)
d) Employees Benefits Expenses	216.21	223.84	198.16	929.43	219.93	246.79	198.16	952.38
e) Finance Cost	23.95	-	16.39	56.85	23.95	-	16.39	56.85
f) Depreciation and Amortisation Expenses	69.24	66.68	56.96	249.92	69.24	66.68	56.96	249.92
g) Other expenses	310.11	440.46	329.15	1,732.59	313.54	502.92	329.15	1,795.05
Total Expenses	2,314.66	1,442.11	2,684.98	10,264.71	2,462.93	2,123.65	2,684.98	10,946.24
3 Profit/(Loss) before Exceptional Items & Tax (1 - 2)	305.27	200.86	431.77	1,660.39	323.82	338.49	431.77	1,798.02
4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-
5 Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	305.27	200.86	431.77	1,660.39	323.82	338.49	431.77	1,798.02
6 Tax Expenses								
Current Year	92.30	53.98	111.00	459.52	96.94	88.39	111.00	493.93
MAT Credit Entitlement	-	-	-	-	-	-	-	-
Deferred Tax Liability	2.48	0.77	(7.36)	(25.03)	2.48	0.77	(7.36)	(25.03)
Total Tax Expense	94.77	54.75	103.64	434.49	99.41	89.16	103.64	468.90
7 Net Profit /Loss for the period from Continuing operation (5- 6)	210.49	146.11	328.13	1,225.89	224.41	249.33	328.13	1,329.12
8 Other Comprehensive Income								
Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	210.49	146.11	328.13	1,225.89	224.41	249.33	328.13	1,329.12
10 Paid up equity share capital (Rs. 10/- per share)	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66	1,221.66
11 Earning Per Share (Rs.)								
Basic	1.72	1.20	2.75	10.09	1.84	2.05	2.75	10.94
Diluted	1.72	1.20	2.75	10.09	1.84	2.05	2.75	10.94

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 13th August 2020.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- Limited review Report has been carried out by the Statutory Auditors for the above period.
- Due to Covid-19, top line & bottom line have been impacted during the current quarter otherwise gross margins, EBITDA & PAT all on uptrend.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 13.08.2020

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To

**The Board of Directors,
Medicamen Biotech Limited**
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019

1. We have reviewed the accompanying statement of unaudited standalone financial results of M/s Medicamen Biotech Limited having its Registered Office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended June 30, 2020 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rai Qimat & Associates
Chartered Accountants**

**Place: Gurugram
Date: 13.08.2020**


**Rai Qimat Rai Garg
(Partner)**
(Membership Number: 080857)
UDIN: 20080857AAAABP1852

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors,
Medicamen Biotech Limited**
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019

1. We have reviewed the Unaudited Consolidated Financial Results of Medicamen Biotech Limited (the "Parent Company"), and the Subsidiary Company for the quarter ended June 30, 2020 which are included in the accompanying 'Statement of Consolidated Unaudited Financial Results for the quarter ended June 30, 2020' (the "Statement"). The Statement is being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the Parent Company's Management and approved by the Parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd (the "Subsidiary" Company)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Consolidated Unaudited Financial Results also includes the Group's share of net profit after tax of Rs. 210.49 Lakhs for the quarter ended June 30, 2020, as considered in the consolidated unaudited financial results, in respect of an subsidiary, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

**For Rai Qimat & Associates
Chartered Accountants**


Rai Qimat & Associates
(Partner)

**(Membership Number: 080857)
UDIN: 20080857AAAABP1852**

**Place: Gurugram
Date: 13.08.2020**



Investor Presentation June 2020

Medicamen Biotech Limited



Committed for **affordable quality healthcare** and aiming leadership through continual improvement and technology

Safe Harbour Statement

This document contains certain forward looking statements with respect to the financial condition, results of operations and business of Medicamen Biotech Limited (“MBL”) and certain of the plans and objectives of MBL with respect to these items. By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward looking statements. These factors include, but are not limited to, domestic and global economic and business conditions, the successful implementation of our strategy and our ability to realize the benefits of this strategy, our ability to develop and market new products, etc. As a result, MBL’s actual future results may differ materially from the plans, goals and expectations set forth in such forward looking statements. MBL does not undertake any obligation to update such forward looking statements to reflect events or circumstances after the date thereof.

Overview



Business Area

- Vertically integrated pharmaceutical company with presence across geographies – India, Latin America, Africa & rest of world (ROW)
- Developing, manufacturing and marketing of finished dosages across wide range of therapeutic domains
- Strong focus on R&D with over 45 employees dedicated to R&D
- **New Oncology formulation plant at Haridwar got manufacturing/drug license from Drug Controlling & Licensing Authority, Uttarakhand**

Subsidiary

- In Australia, strong portfolio with 14 products

Production site

Three Manufacturing state of the art facilities


- 2 General facility in Bhiwadi & Haridwar
- 1 Oncology facility in Haridwar

Certification


- Certified by WHO, ANVISA (Brazil), NAFDAC, MCAZ and DACA etc

Overall Snapshot - Consolidated


Quarterly Revenue and Growth



Quarterly PAT margin and Growth %




Quarterly EBITDA margin and Growth %




Due to Covid-19, top line & bottom line have been impacted during the current otherwise gross margins, EBITDA & PAT all on uptrend.

Overall Snapshot - Standalone


Quarterly Revenue and Growth



Quarterly PAT margin and Growth %



Quarterly EBITDA margin and Growth %



Due to Covid-19, top line & bottom Line have been impacted during the current quarter otherwise gross margins, EBITDA & PAT all on uptrend

Overall Snapshot (Quarterly) - Consolidated

INR Lacs	Q1'FY21	Q4'FY20	Q1'FY20
Revenue from Operations	2,778	2,352	3,113
Other Income	8	110	4
Total Income	2,787	2,462	3,117
COGS	1,836	1,307	2,084
Employee Benefit Expenses	220	247	198
Finance Costs	24	-	16
Depreciation	69	67	57
Other Expenses	314	503	329
Total Expenses	2,463	2,124	2,685
Profit Before Tax	324	338	432
Tax	99	89	104
Profit After Tax	224	249	328

Overall Snapshot (Quarterly) - Standalone

INR Lacs	Q1'FY21	Q4'FY20	Q1'FY20
Revenue from Operations	2,612	1,536	3,113
Other Income	8	107	4
Total Income	2,620	1,643	3,117
COGS	1,695	711	2,084
Employee Benefit Expenses	216	224	198
Finance Costs	24	-	16
Depreciation	69	67	57
Other Expenses	310	440	329
Total Expenses	2,315	1,442	2,685
Profit Before Tax	305	201	432
Tax	95	55	104
Profit After Tax	210	146	328

Manufacturing facilities of Medicamen Biotech

Bhiwadi Plant

Location: Rajasthan

Facility divided into six separate blocks

Beta Lactum Block

- Tablets
- Capsules
- Dry syrups

Non-Beta Lactum Block

- Tablets
- Capsules
- Dry syrups

ORS and Liquid Orals Block

Warehouse and Quality Assurance / Quality Control Block

Formulation Development, Analytical and Chemical Research Development

Finished Goods Store Block

Haridwar Plant (Unit I)

Location: Uttrakhand

Facility has a single three-storied unit

Non Betalactum Tablets

Non-Betalactum Capsules

- Liquid orals
- External ointments

Haridwar Plant (Unit II)

Location: Uttrakhand

Dedicated plant to manufacture oncology products

Tablets

Capsules

Injectables

Lyophilizers

US-FDA and EU compliant facility with state-of-the-art plant and machinery

Manufacturing facilities of Medicamen Biotech

The company initiated commercial production in 1996



**Bhiwadi
Plant**

Covered area: 120,000 square feet
General pharmaceutical formulation
division



**Haridwar Plant
(Unit I)**

Covered area: 32,000 square feet
General pharmaceutical formulation
division



**Haridwar Plant
(Unit II)**

Covered area: 35,000 square
feet Oncology formulation
division

Global presence




ONCOLOGY PLANT AT HARIDWAR COMMENCED OPERATIONS RECENTLY



Rationale for oncology product selection


1

Products having
global sales
more than
US\$1b



3

Substantial
value
expectation
in times to
come



2

Easy market entry
with no IP /Patent
hurdle




4

Therapeutic domain
dominance in
specific cancer area



Robust R&D Capabilities



Strength of R&D ~ 45 employees

- State-of-art R&D set up duly approved from Department of Scientific and Industrial Research (DSIR), Govt of India
- Development facility at **Bhiwadi** for development of Active Pharma Ingredients (API) and Intermediates along with Formulations R&D.
- Backed by the team of highly professional and well-experienced team of researchers and scientist for development of new products.

Bhiwadi Plant



New Oncology Plant - Haridwar



A dark blue background featuring a faint, stylized molecular structure with interconnected circles and lines, resembling a network or a chemical compound.

Thank you!

Medicamen Biotech Limited

REGISTERED OFFICE

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi - 110019

Phone 011-47589500 (30 Lines) | **Fax** 011-26213081 | **E-mail** cs@medicamen.com

Website www.medicamen.com